<DOC>
	<DOCNO>NCT00326118</DOCNO>
	<brief_summary>The purpose primary phase study demonstrate non-inferiority single dose GSK Biologicals ' Haemophilus influenzae type b meningococcal C ( Hib-MenC ) conjugate vaccine give second year life subject prim infancy Hib vaccine , meningococcal serogroup C vaccine , versus commercially available Hib MenC vaccine . In extension phase , Years 1 , 2 , 3 , 4 &amp; 5 , one blood sample take year follow antibody persistence 5 year vaccination . No additional vaccine administer extension phase . The Protocol Posting update order comply FDA Amendment Act , Sep 2007 .</brief_summary>
	<brief_title>Study Toddlers Demonstrate Non-inferiority GSK Biologicals ' Hib-MenC &amp; Evaluate Persistence 5 Years .</brief_title>
	<detailed_description>This multicenter study open 2 treatment group Hiberix™ + commercially available MenC vaccine active control . Priorix™ give concomitantly group . In primary phase , two blood sample take subject immunogenicity analysis : one month vaccination . In extension phase , Year 1 , 2 , 3 , 4 &amp; 5 , one blood sample take year follow antibody persistence 5 year vaccination . No additional vaccine administer extension phase .</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Primary phase : Subjects investigator believe parents/guardians comply requirement protocol . A male female , include , 12 18 month age time vaccination . Written inform consent obtain parent guardian subject . Free obvious health problem establish medical history clinical examination enter study . Previously complete routine childhood vaccination best his/her parents'/guardians knowledge . Having complete primary vaccination two dos Haemophilus influenzae type b outer membrane protein ( HibOMP ) contain vaccine OR three dos diphtheria , tetanus , acellular pertussis Haemophilus influenzae type b ( DTPa/Hib ) contain vaccine least 6 month study start . Longterm persistence phase : Having participate vaccination study 106445 For primary vaccination phase : Use investigational nonregistered product ( drug vaccine ) study vaccine ( ) within 30 day precede first dose study vaccine , plan use study period . Chronic administration ( defined 14 day ) plan administration immunosuppressant immunemodifying drug within six month prior vaccination . Planned administration/administration vaccine foreseen protocol period start 30 day vaccination end 30 day vaccination . Administration meningococcal vaccine foreseen study protocol period start birth end first dose . Previous administration booster dose Hib vaccine . Previous vaccination measles , mumps , rubella . History H. influenzae type b , meningococcal serogroup C and/or confirm measles , mumps rubella disease . Known exposure measles , mumps rubella within 30 day prior start study . Any confirm suspected immunosuppressive immunodeficient condition , include human immunodeficiency virus infection . A family history congenital hereditary immunodeficiency . History allergic disease reaction likely exacerbate component vaccine . Major congenital defect serious chronic illness . History neurological disorder one episode febrile convulsion . Acute disease time enrolment . Administration immunoglobulins and/or blood product since birth plan administration study period . Additional exclusion criterion longterm persistence phase : checked year . Previous administration booster dose Hib , meningococcal serogroup C vaccine . History H. influenzae type b , meningococcal serogroup C diseases .</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>18 Months</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Meningococcal serogroup C disease</keyword>
	<keyword>H.influenzae type b disease</keyword>
</DOC>